Opinion|Videos|December 17, 2024
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.
Advertisement
Episodes in this series
- Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
